Market Place
Sourcing Support
Fulcrum Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Oct 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Rule
13 Sep 2024 //
GLOBENEWSWIRE
Fulcrum stock slumps after muscle disorder drug fails in late-stage study
13 Sep 2024 //
REUTERS
Fulcrum Therapeutics to Participate in Upcoming September Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
23 Aug 2024 //
GLOBENEWSWIRE
Fulcrum Adds Chief Commercial Officer And Chief Regulatory Affairs Officer
19 Aug 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics Reports Inducement Grants
09 Aug 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics Reports Q2 2024 Results And Business Highlights
31 Jul 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics To Host Q2 2024 Results Call On July 31
24 Jul 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics To Present At FSHD Research Congress
12 Jun 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics To Participate At Goldman Healthcare Conference
06 Jun 2024 //
GLOBENEWSWIRE
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
14 May 2024 //
BIOPHARMADIVE
Fulcrum Announces Business Highlights, Q1 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics to Participate in Upcoming May Conferences
09 May 2024 //
GLOBENEWSWIRE
Fulcrum Losmapimod FSHD Study Published In Lancet Neurology
08 May 2024 //
GLOBENEWSWIRE
Fulcrum To Host Q1 2024 Results Call, Webcast On May 13
06 May 2024 //
GLOBENEWSWIRE
Fulcrum to Participate at the Cantor Virtual Muscular Dystrophy Symposium
28 Mar 2024 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Mar 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
18 Mar 2024 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule
08 Mar 2024 //
GLOBENEWSWIRE
Fulcrum to Participate at the Leerink Partners Global Biopharma Conference
05 Mar 2024 //
GLOBENEWSWIRE
Fulcrum Announces Financial Results for Fourth Quarter and Full Year 2023
27 Feb 2024 //
GLOBENEWSWIRE
Fulcrum to Host Fourth Quarter and Full Year 2023 Financial Results Conference
20 Feb 2024 //
GLOBENEWSWIRE
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Dec 2023 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Nov 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
09 Nov 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Announces Financial Results for Third Quarter 2023
07 Nov 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference
31 Oct 2023 //
GLOBENEWSWIRE
Fulcrum to Participate at the Cantor Fitzgerald Global Healthcare Conference
22 Sep 2023 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Sep 2023 //
GLOBENEWSWIRE
Fulcrum Announces Completion of Enrollment in the Phase 3 Trial of Losmapimod
07 Sep 2023 //
GLOBENEWSWIRE
Fulcrum`s SCD program is back in business after FDA lifts hold
22 Aug 2023 //
FIERCE BIOTECH
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Aug 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Appoints Chief Financial Officer
03 Aug 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Announces Financial Results for Second Quarter 2023
03 Aug 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference
27 Jul 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
10 Jul 2023 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jul 2023 //
GLOBENEWSWIRE
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery
20 Jun 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
15 May 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Announces Recent Business Highlights and FYR for the1Q 2023
15 May 2023 //
GLOBENEWSWIRE
Still under clinical hold, Fulcrum locks in seasoned commercial leader as CEO
15 May 2023 //
ENDPTS
Fulcrum Therapeutics to Host 1Q 2023 FYR Conference Call and Webcast
08 May 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
05 May 2023 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Apr 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Announces CFO Resignation
05 Apr 2023 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Mar 2023 //
GLOBENEWSWIRE
Cancer concerns behind FDA hold on Fulcrum`s sickle cell med
10 Mar 2023 //
FIERCE BIOTECH
Fulcrum Announces Financial Results for Fourth Quarter and Full Year 2022
09 Mar 2023 //
GLOBENEWSWIRE
Fulcrum to Host Fourth Quarter and Full Year 2022 Financial Results Conference
06 Mar 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
25 Feb 2023 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Feb 2023 //
GLOBENEWSWIRE
Fulcrum to Participate at Upcoming SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
With CEO search, PhIII study underway, Fulcrum raises $125M from stock offering
18 Jan 2023 //
ENDPTS
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
17 Jan 2023 //
GLOBENEWSWIRE
Fulcrum Announces Pricing of Upsized Public Offering of Common Stock
17 Jan 2023 //
GLOBENEWSWIRE
Fulcrum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Jan 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Announces CEO Transition
04 Jan 2023 //
GLOBENEWSWIRE
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
04 Jan 2023 //
GLOBENEWSWIRE
